Recent advances in cardiology – Hot trials from the American Heart Association Annual Scientific Meeting 2023
| Autor: | Akshyaya Pradhan, Sudesh Prajapati, Pravesh Vishwakarma |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Heart India, Vol 12, Iss 2, Pp 57-62 (2024) |
| Druh dokumentu: | article |
| ISSN: | 2321-449X 2321-6638 |
| DOI: | 10.4103/heartindia.heartindia_20_24 |
| Popis: | Cardiovascular (CV) diseases are the leading causes of death worldwide in both sexes alike. However, there have been significant developments in CV pharmacotherapy, percutaneous intervention, and systems of care over the past three decades in parallel. Several landmark studies were presented and discussed in American Heart Association (AHA) 2023 Scientific Sessions held in Philadelphia. The dapagliflozin-myocardial infarction (MI) and SELECT discussed the CV benefits of newer antidiabetic drugs. The AZALEA-TIMI and ARTESIA evaluated newer anticoagulants in atrial fibrillation. VERVE-101 and LEPODISIRAN studies were related to lipid-lowering in clinical practice. The ESPRIT trial demonstrated the benefits of intensive blood lowering, while KARDIA-1 tested a new RNA-based therapeutic agent for blood pressure lowering. The MINT trial evaluated strategies for blood transfusion in anemia concomitant with acute MI. ORBITA-2 study demonstrated the positive impact of percutaneous coronary intervention for angina control in stable coronary artery disease. Hence, these studies encompassed almost all aspects of cardiology, including heart failure, acute coronary syndrome, lipidology, anticoagulation, hypertension, obesity, and coronary intervention. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|